In colloquial terms, "breakthrough" connotes an important, definitive advance. Since the 2012 US Food and Drug Administration (FDA) Safety and Innovation Act became law, however, the FDA can assign the breakthrough designation to a drug that "treats a serious or lifethreatening condition" and "may demonstrate a substantial improvement…over available therapies" based only on preliminary evidence (eg, uncontrolled studies, surrogate outcomes).
1 Such drugs often receive "accelerated approval." [2] [3] [4] All FDA press releases announcing approval of breakthrough-designated drugs use the term breakthrough; about half use promising. 4, 5 Patients can easily find these press releases searching the Internet or hearing about them in the news. Unless patients understand the FDA's usage of breakthrough, they may have unwarranted confidence in the evidence supporting drug claims. In a randomized trial, we test how these terms affect lay judgments (NCT02428556).
Methods | We recruited an online sample of 597 Americans (mean age, 36 years [range, 19-83 years] ; 41% were women; 55% had a college and/or graduate degree) in June 2014 from an online service (Amazon's Mechanical Turk [MTurk] ). Participants received $1 for completing "a 10-minute medical drug survey."
Participants were randomized to 1 of 5 vignettes-short descriptions of a recently approved drug (Table 1) , based on an FDA press release for a metastatic lung cancer breakthrough drug conditionally approved based on the surrogate outcome tumor shrinkage. The facts-only condition described the drug as meeting the breakthrough criteria, but without using the term. The breakthrough and promising conditions added those terms. The tentative explanation used FDA-required language for professional labeling. The definitive explanation changed "may be contingent" to "is contingent." Participants judged the drug's benefit, harm, and strength of evidence (Table 2 includes full question text). A Kruskal-Wallis test was performed followed by Mann-Whitney U-tests comparing individual groups. A Bonferroni-correction accounted for multiple comparisons, α = .01 (IBM SPSS Statistics; version 23.0).
Results | Adding either description (promising or breakthrough) increased the percentage of participants rating the drug as "very" or "completely effective" compared with factsonly: 23% and 25% vs 11%; P = .002 and P = .001 (Table 2) . It significantly increased the percentage believing that the evidence supporting the drug is "strong" or "extremely strong": To test the effect of calling a drug "breakthrough" or "promising," the reference group was facts-only (the first set of P values). To test the effect of the explanations, the reference group was "breakthrough" (the second set of P values) (see Results section). b Short descriptions of recently approved drugs. See the Methods section for definitions.
59% and 63% vs 43%; P = .006 and P = .003. Adding either explanation reduced the breakthrough effect on judged drug effectiveness and evidence quality. Both explanations significantly reduced the percentage of respondents incorrectly believing the drug had been "proven to save lives": 16% (tentative) and 10% (definitive) vs 31% (breakthrough); P = .006 and P <.001. Perceived drug safety was similar in all groups.
A final question in all conditions asked participants which of 2 drugs they would take for a potentially deadly condition: one described as "breakthrough," the other described as meeting the breakthrough criteria. Ninety-two chose the "breakthrough drug."
Conclusions | The terms breakthrough and promising increased people's beliefs in a drug's effectiveness and strength of supporting evidence compared with describing the drug as meeting the breakthrough criteria, but without using those descriptors. The breakthrough effect was mitigated by explaining the regulatory meaning of accelerated approval (as required in the professional label). One study limitation is the sample, who were volunteers, younger, and better educated than the general public. Although MTurk samples often respond similarly to nationally representative ones 6 we can only speculate about possible differences herein. A second limitation is using a hypothetical drug, albeit with information adapted from an actual FDA press release, hence similar to what people might encounter in their everyday lives. While the name "breakthrough therapy designation" is specified by law, FDA is not required to use the name or terms like promising in press releases. Press releases with neutral terms-and that routinely explain the limited evidence supporting accelerating approval-might help consumers make more accurate judgments about these drugs. 1 created a new regulatory review designation-breakthrough therapy-that would expedite the development and FDA review of as-yet unapproved drugs and biologic agents intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drugs may offer substantial improvement over existing therapies. This legislation was likely enacted to promote innovative drug development and to respond to critics of the FDA regulatory review process, who criticize it as being slow despite research demonstrating the opposite. Reflecting these intentions, the term developed by Congress and adopted by the FDA for this new review designationbreakthrough therapy-is aspirational. In this issue of JAMA Internal Medicine, Krishnamurti et al 3 examine the impact of this terminology. They report a ran-
